With the 1,8 billion RMB acquisition, Guan Hao Biotech will become China’s second largest pharmaceutical enterprise and extend ist business into regenerative medicine, cell therapy and other drugs. Huidisen is a leader in cephalosporin production.
China Bio news release, October 24, 2016